KYMR

Company Overview — What Does Kymera Therapeutics, Inc. Do?

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Kymera Therapeutics, Inc. (KYMR) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Nello Mainolfi and employs approximately 170 people. With a market capitalization of $6.9B, KYMR is one of the notable companies in the Healthcare sector.

Kymera Therapeutics, Inc. (KYMR) Stock Rating — Hold (April 2026)

As of April 2026, Kymera Therapeutics, Inc. receives a Hold rating with a composite score of 36.8/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.KYMR ranks #1,880 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Kymera Therapeutics, Inc. ranks #196 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

KYMR Stock Price and 52-Week Range

Kymera Therapeutics, Inc. (KYMR) currently trades at $85.06. The stock lost $2.29 (2.6%) in the most recent trading session. The 52-week high for KYMR is $103.00, which means the stock is currently trading -17.4% from its annual peak. The 52-week low is $19.45, putting the stock 337.4% above its annual trough. Recent trading volume was 400K shares, suggesting relatively thin trading activity.

Is KYMR Overvalued or Undervalued? — Valuation Analysis

Kymera Therapeutics, Inc. (KYMR) carries a value factor score of 28/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.40x, versus the sector average of 2.75x. The price-to-sales ratio is 173.34x, compared to 1.66x for the average Healthcare stock.

At current multiples, Kymera Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Kymera Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Kymera Therapeutics, Inc. (KYMR) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -18.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -16.5% versus the sector average of -33.1%.

On a margin basis, Kymera Therapeutics, Inc. reports gross margins of 0.0%, compared to 71.5% for the sector. The operating margin is -1587.2% (sector: -66.1%). Net profit margin stands at -1401.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -89.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

KYMR Debt, Balance Sheet, and Financial Health

Kymera Therapeutics, Inc. has a debt-to-equity ratio of 10.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 10.47x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $113M.

KYMR has a beta of 1.39, meaning it is more volatile than the broader market — a $10,000 investment in KYMR would be expected to move 39.1% more than the S&P 500 on any given day. The stability factor score for Kymera Therapeutics, Inc. is 36/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Kymera Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Kymera Therapeutics, Inc. reported revenue of $40M and earnings per share (EPS) of $-3.69. Net income for the quarter was $-287M. Gross margin was 0.0%. Operating income came in at $-324M.

In FY 2025, Kymera Therapeutics, Inc. reported revenue of $39M and earnings per share (EPS) of $-3.69. Net income for the quarter was $-311M. Gross margin was 0.0%. Revenue grew -16.7% year-over-year compared to FY 2024. Operating income came in at $-349M.

In Q3 2025, Kymera Therapeutics, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.94. Net income for the quarter was $-82M. Gross margin was 0.0%. Revenue grew -26.1% year-over-year compared to Q3 2024. Operating income came in at $-93M.

In Q2 2025, Kymera Therapeutics, Inc. reported revenue of $11M and earnings per share (EPS) of $-0.95. Net income for the quarter was $-77M. Gross margin was 0.0%. Revenue grew -55.3% year-over-year compared to Q2 2024. Operating income came in at $-85M.

Over the past 8 quarters, Kymera Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $26M to $40M. Investors analyzing KYMR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

KYMR Dividend Yield and Income Analysis

Kymera Therapeutics, Inc. (KYMR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

KYMR Momentum and Technical Analysis Profile

Kymera Therapeutics, Inc. (KYMR) has a momentum factor score of 70/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

KYMR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Kymera Therapeutics, Inc. (KYMR) ranks #196 out of 838 stocks based on the Blank Capital composite score. This places KYMR in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing KYMR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full KYMR vs S&P 500 (SPY) comparison to assess how Kymera Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

KYMR Next Earnings Date

No upcoming earnings date has been announced for Kymera Therapeutics, Inc. (KYMR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy KYMR? — Investment Thesis Summary

Kymera Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 25/100 flags below-average profitability. The value score of 28/100 indicates premium valuation. Price momentum is positive at 70/100, suggesting the trend favors buyers. High volatility (stability score 36/100) increases portfolio risk.

In summary, Kymera Therapeutics, Inc. (KYMR) earns a Hold rating with a composite score of 36.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on KYMR stock.

Related Resources for KYMR Investors

Explore more research and tools: KYMR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare KYMR head-to-head with peers: KYMR vs AZN, KYMR vs SLGL, KYMR vs VMD.